Feature Channels: Clinical Trials

• share
• favorite_border

Recent results from one of the I-SPY 2.2 study arms, published September 14, 2024 in Nature Medicine, showed that neoadjuvant treatment with the antibody-drug conjugate datopotamab–deruxtecan (Dato-DXd) in combination with the immune checkpoint inhibitor, durvalumab (Imfinzi), produced high rates of pCR in patients who have an immune breast cancer subtype as well as a subtype of triple negative cancer that would ordinarily have a high risk of recurrence.

• share
• favorite_border

Researchers from the UChicago Medicine Comprehensive Cancer Center published results from a clinical trial evaluating a novel combination treatment for advanced bladder cancer.

• share
• favorite_border

People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy — proton beam therapy or intensity modulated radiation therapy (IMRT) — achieved equally high rates of tumor control with no differences in patient-reported quality of life, according to a first-of-its-kind phase III clinical trial comparing the two technologies. Findings of the PARTIQoL trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

• share
• favorite_border

Largest Global Gathering of Kidney Professionals Expands Program to Include More Breaking Research and Focused Discussions on Key Public Health and Policy Issues

• share
• favorite_border

A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar benefits to patients with difficult-to-treat meningioma, a type of brain tumor. Findings of the nonrandomized phase II study will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

• share
• favorite_border

The annual meeting will feature 23 abstracts from UCLA investigators that highlight key areas of radiation oncology, including new research in subspecialties ranging from survivorship, lung cancer/thoracic malignancies, physics, sarcoma, gastrointestinal cancer, genitourinary cancer, gynecological cancer, pediatric cancer and diversity, equity and inclusion in healthcare.

• share
• favorite_border

Leading experts in radiation therapy from Penn Medicine’s Abramson Cancer Center and the Perelman School of Medicine will present new results from clinical trials and research studies at the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting.

• share
• favorite_border

The University of Pittsburgh Schools of the Health Sciences has been awarded approximately $100 million from the U.S. Department of Defense to continue a clinical research program that is advancing trauma care.

• share
• favorite_border

Using genomics and early treatment response to guide risk-stratification and low-intensity therapy use for ETV6::RUNX1 and high-hyperdiploid B-cell acute lymphoblastic leukemia benefits patients.

• share
• favorite_border

Mayo Clinic in Florida has received a grant from the National Institute of Neurological Disorders and Stroke (NIDS) to begin an innovative study that will provide hundreds of patients with amyotrophic lateral sclerosis (ALS) access to the experimental drug ibudilast over six months.

• share
• favorite_border

The #HOPE4LIVER trials, testing the safety efficacy of histotripsy as a treatment for primary and metastatic liver tumors, met its goals for technical success and safety. An expert is quoted explaining the results.

• share
• favorite_border

The University of Kansas Cancer Center is part of the myeloMATCH trial, a large, coordinated effort to improve patient outcomes through targeted treatments for people with acute myeloid leukemia or myelodysplastic syndrome.

• share
• favorite_border

Dr. Jeremie Calais received two grants from Novartis totaling $4 million aimed at improving the effectiveness of the radiation-emitting targeted therapy 177-Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC), one of the most challenging forms of the disease.

• share
• favorite_border

UCLA investigators have developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the disease and better identify therapies that are most likely to work for each individual patient.

• share
• favorite_border

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer. The results, which were recently published in JAMA Oncology, show potential to broaden the number of patients with bladder cancer who could benefit from immunotherapy, an approach that harnesses a patient's own immune system to fight cancer.

• share
• favorite_border

UTHealth Houston has enrolled the first patient in the Southeastern United States into a national Phase I/II clinical trial testing whether a neural cell therapy product can help inhibit the abnormal electrical activity that leads to an epileptic seizure.

• share
• favorite_border

CLEVELAND: A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in 5,000 people worldwide.